annual CFF:
-$4.19B-$2.43B(-138.38%)Summary
- As of today (September 17, 2025), TAK annual cash flow from financing activities is -$4.19 billion, with the most recent change of -$2.43 billion (-138.38%) on March 1, 2025.
- During the last 3 years, TAK annual CFF has risen by +$4.37 billion (+51.08%).
- TAK annual CFF is now -115.58% below its all-time high of $26.88 billion, reached on March 31, 2019.
Performance
TAK Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$1.37B+$355.28M(+20.57%)Summary
- As of today (September 17, 2025), TAK quarterly cash flow from financing activities is -$1.37 billion, with the most recent change of +$355.28 million (+20.57%) on June 1, 2025.
- Over the past year, TAK quarterly CFF has dropped by -$3.50 billion (-164.42%).
- TAK quarterly CFF is now -109.65% below its all-time high of $14.22 billion, reached on March 31, 2019.
Performance
TAK quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$7.68B-$3.50B(-83.84%)Summary
- As of today (September 17, 2025), TAK TTM cash flow from financing activities is -$7.68 billion, with the most recent change of -$3.50 billion (-83.84%) on June 1, 2025.
- Over the past year, TAK TTM CFF has dropped by -$8.33 billion (-1278.89%).
- TAK TTM CFF is now -128.56% below its all-time high of $26.89 billion, reached on March 31, 2019.
Performance
TAK TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
TAK Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -138.4% | -164.4% | -1278.9% |
| 3 y3 years | +51.1% | +7.7% | -17.5% |
| 5 y5 years | +48.1% | +9.3% | +6.5% |
TAK Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -138.4% | +51.1% | -164.4% | +66.1% | -958.6% | at low |
| 5 y | 5-year | -138.4% | +54.7% | -164.4% | +66.1% | -958.6% | +32.5% |
| alltime | all time | -115.6% | +54.7% | -109.7% | +75.6% | -128.6% | +32.5% |
TAK Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$1.37B(-20.6%) | -$7.68B(+83.8%) |
| Mar 2025 | -$4.19B(+138.4%) | -$1.73B(-57.4%) | -$4.18B(+54.3%) |
| Dec 2024 | - | -$4.05B(+665.1%) | -$2.71B(-402.7%) |
| Sep 2024 | - | -$529.28M(-124.9%) | $894.22M(+37.3%) |
| Jun 2024 | - | $2.13B(-926.1%) | $651.27M(-137.1%) |
| Mar 2024 | -$1.76B(-60.4%) | -$257.80M(-42.5%) | -$1.75B(+17.8%) |
| Dec 2023 | - | -$448.27M(-42.0%) | -$1.49B(-61.8%) |
| Sep 2023 | - | -$772.23M(+179.8%) | -$3.90B(+20.3%) |
| Jun 2023 | - | -$276.03M(-3793.3%) | -$3.24B(-27.2%) |
| Mar 2023 | -$4.43B(-48.2%) | $7.47M(-100.3%) | -$4.45B(-30.1%) |
| Dec 2022 | - | -$2.86B(+2441.1%) | -$6.37B(+36.2%) |
| Sep 2022 | - | -$112.57M(-92.4%) | -$4.68B(-28.4%) |
| Jun 2022 | - | -$1.49B(-22.1%) | -$6.53B(-24.0%) |
| Mar 2022 | -$8.56B(-7.4%) | -$1.91B(+63.0%) | -$8.59B(-14.5%) |
| Dec 2021 | - | -$1.17B(-40.6%) | -$10.05B(-11.8%) |
| Sep 2021 | - | -$1.97B(-44.4%) | -$11.38B(+0.1%) |
| Jun 2021 | - | -$3.55B(+5.5%) | -$11.37B(+21.8%) |
| Mar 2021 | -$9.25B(+14.5%) | -$3.36B(+34.0%) | -$9.34B(+32.9%) |
| Dec 2020 | - | -$2.51B(+28.3%) | -$7.03B(+54.5%) |
| Sep 2020 | - | -$1.95B(+29.3%) | -$4.55B(-44.6%) |
| Jun 2020 | - | -$1.51B(+43.6%) | -$8.21B(+2.2%) |
| Mar 2020 | -$8.08B(-130.0%) | -$1.05B(+3390.4%) | -$8.03B(-210.9%) |
| Dec 2019 | - | -$30.16M(-99.5%) | $7.24B(-65.2%) |
| Sep 2019 | - | -$5.62B(+321.2%) | $20.78B(-20.9%) |
| Jun 2019 | - | -$1.33B(-109.4%) | $26.28B(-2.2%) |
| Mar 2019 | $26.88B(-1037.4%) | $14.22B(+5.3%) | $26.89B(+137.1%) |
| Dec 2018 | - | $13.51B(<-9900.0%) | $11.34B(-512.1%) |
| Sep 2018 | - | -$110.57M(-84.9%) | -$2.75B(-1.9%) |
| Jun 2018 | - | -$730.39M(-45.0%) | -$2.80B(-1.6%) |
| Mar 2018 | -$2.87B(-204.6%) | -$1.33B(+128.9%) | -$2.85B(-436.2%) |
| Dec 2017 | - | -$580.75M(+255.7%) | $847.64M(+5.7%) |
| Sep 2017 | - | -$163.27M(-79.0%) | $802.07M(-9.2%) |
| Jun 2017 | - | -$776.79M(-132.8%) | $882.92M(-67.4%) |
| Mar 2017 | $2.74B(-374.5%) | $2.37B(-478.2%) | $2.71B(+313.2%) |
| Dec 2016 | - | -$626.31M(+659.8%) | $656.09M(-12.8%) |
| Sep 2016 | - | -$82.43M(-107.8%) | $752.62M(-0.9%) |
| Jun 2016 | - | $1.05B(+234.9%) | $759.31M(-175.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | -$998.88M(-61.5%) | $313.81M(-159.2%) | -$1.00B(-58.6%) |
| Dec 2015 | - | -$529.78M(+599.4%) | -$2.42B(-1.2%) |
| Sep 2015 | - | -$75.74M(-89.3%) | -$2.45B(-6.4%) |
| Jun 2015 | - | -$708.97M(-35.7%) | -$2.62B(-2.3%) |
| Mar 2015 | -$2.59B(-355.9%) | -$1.10B(+97.4%) | -$2.68B(+70.1%) |
| Dec 2014 | - | -$558.99M(+128.7%) | -$1.57B(+55.1%) |
| Sep 2014 | - | -$244.44M(-68.3%) | -$1.01B(+31.7%) |
| Jun 2014 | - | -$770.10M(+495.6%) | -$770.10M(-55.4%) |
| Mar 2014 | $1.01B(-155.2%) | - | - |
| Mar 2013 | -$1.84B(-136.8%) | - | - |
| Mar 2012 | $4.99B(-391.4%) | - | - |
| Mar 2011 | -$1.71B(+7.3%) | -$129.30M(-83.1%) | -$1.73B(-0.2%) |
| Dec 2010 | - | -$765.37M(+475.0%) | -$1.73B(+3.9%) |
| Sep 2010 | - | -$133.11M(-81.0%) | -$1.66B(+1.8%) |
| Jun 2010 | - | -$699.06M(+429.4%) | -$1.63B(+1.8%) |
| Mar 2010 | -$1.59B(-62.3%) | -$132.06M(-81.1%) | -$1.61B(+9.0%) |
| Dec 2009 | - | -$699.81M(+574.6%) | -$1.47B(+90.4%) |
| Sep 2009 | - | -$103.73M(-84.5%) | -$773.86M(+15.5%) |
| Jun 2009 | - | -$670.12M | -$670.12M |
| Mar 2009 | -$4.23B(+84.6%) | - | - |
| Mar 2008 | -$2.29B(-15.1%) | - | - |
| Mar 2007 | -$2.70B(+242.6%) | - | - |
| Mar 2006 | -$788.85M(+14.7%) | - | - |
| Mar 2005 | -$687.62M(+30.9%) | - | - |
| Mar 2004 | -$525.17M(+8.5%) | - | - |
| Mar 2003 | -$483.93M(+14.8%) | - | - |
| Mar 2002 | -$421.40M(+11.2%) | - | - |
| Mar 2001 | -$378.99M(+51.2%) | - | - |
| Mar 2000 | -$250.60M(+39.2%) | - | - |
| Mar 1999 | -$180.07M(+12.7%) | - | - |
| Mar 1998 | -$159.73M(+18.6%) | - | - |
| Mar 1997 | -$134.69M(-16.4%) | - | - |
| Mar 1996 | -$161.04M(-40.9%) | - | - |
| Mar 1995 | -$272.59M(+100.6%) | - | - |
| Mar 1994 | -$135.89M(+83.5%) | - | - |
| Mar 1993 | -$74.07M(-18.5%) | - | - |
| Mar 1992 | -$90.92M(+16.4%) | - | - |
| Mar 1991 | -$78.11M | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual cash flow from financing activities?
- What is the all time high annual CFF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual CFF year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly CFF year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM cash flow from financing activities?
- What is the all time high TTM CFF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM CFF year-on-year change?
What is Takeda Pharmaceutical Company Limited annual cash flow from financing activities?
The current annual CFF of TAK is -$4.19B
What is the all time high annual CFF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual cash flow from financing activities is $26.88B
What is Takeda Pharmaceutical Company Limited annual CFF year-on-year change?
Over the past year, TAK annual cash flow from financing activities has changed by -$2.43B (-138.38%)
What is Takeda Pharmaceutical Company Limited quarterly cash flow from financing activities?
The current quarterly CFF of TAK is -$1.37B
What is the all time high quarterly CFF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly cash flow from financing activities is $14.22B
What is Takeda Pharmaceutical Company Limited quarterly CFF year-on-year change?
Over the past year, TAK quarterly cash flow from financing activities has changed by -$3.50B (-164.42%)
What is Takeda Pharmaceutical Company Limited TTM cash flow from financing activities?
The current TTM CFF of TAK is -$7.68B
What is the all time high TTM CFF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM cash flow from financing activities is $26.89B
What is Takeda Pharmaceutical Company Limited TTM CFF year-on-year change?
Over the past year, TAK TTM cash flow from financing activities has changed by -$8.33B (-1278.89%)